Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052671 | 0.93 | ESR1 (0.51) | ESR1ESR2CYP19A1PRSS1THRA | |
| SCHEMBL3817125 | 0.93 | ESR1 (0.54) | ESR1ESR2CYP19A1PRSS1THRA | |
| SCHEMBL3823445 | 0.91 | CYP19A1 (0.50) | ESR1ESR2CYP19A1PRSS1 | |
| SCHEMBL4666434 | 0.89 | ESR1 (0.51) | ESR1ESR2CYP19A1CNR2ESRRG | |
| SCHEMBL4896555 | 0.88 | ESR1 (0.54) | ESR1ESR2CYP19A1PRSS1CNR2 | |
| SCHEMBL3818064 | 0.86 | ESR1 (0.56) | ESR1ESR2CYP19A1PRSS1THRA | |
| SCHEMBL4668880 | 0.86 | CYP19A1 (0.50) | ESR1ESR2CYP19A1CNR2SMPD1 | |
| SCHEMBL4667972 | 0.84 | ESR1 (0.49) | ESR1ESR2CYP19A1CNR2ESRRG | |
| SCHEMBL3813207 | 0.83 | CYP19A1 (0.57) | ESR1ESR2CYP19A1PRSS1 | |
| SCHEMBL5075821 | 0.83 | THRA (0.53) | ESR1ESR2THRATHRBESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234199-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080234199-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080234199-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| WO-2007062148-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234199-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.